Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
| ▸ | DPP4 | P27487 | 2/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 6/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.38 |
| ▸ | LIPE | Q05469 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14815549 | 0.94 | EPHX2 (0.41) | EPHX2DPP4TRPV1HCRTR1HCRTR2 | |
| SCHEMBL14815174 | 0.86 | EPHX2 (0.44) | EPHX2DPP4TRPV1HCRTR1HCRTR2 | |
| SCHEMBL14815306 | 0.86 | EPHX2 (0.43) | EPHX2DPP4TRPV1HCRTR1HCRTR2 | |
| SCHEMBL14815171 | 0.82 | EPHX2 (0.52) | EPHX2DPP4TRPV1HCRTR1HCRTR2 | |
| SCHEMBL14815301 | 0.82 | EPHX2 (0.41) | EPHX2HCRTR1HCRTR2 | |
| SCHEMBL14815455 | 0.80 | MGLL (0.49) | HCRTR1HCRTR2CYP2C9 | |
| SCHEMBL14815318 | 0.77 | HCRTR2 (0.38) | EPHX2HCRTR1HCRTR2CYP3A4CYP2D6 | |
| SCHEMBL14814682 | 0.75 | HCRTR1 (0.40) | HCRTR1HCRTR2 | |
| SCHEMBL14815158 | 0.74 | DPP4 (0.45) | EPHX2DPP4TRPV1CYP3A4CYP2D6 | |
| SCHEMBL14815100 | 0.72 | HCRTR2 (0.41) | EPHX2HCRTR1HCRTR2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130085142-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-04-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085142-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, CACNA1E, CACNA1D | EPHX2 2168/4885DPP4 578/4885TRPV1 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.